The Role of Probiotics in HIV Patients With Immunological Non-Responder

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

December 27, 2018

Study Completion Date

December 27, 2018

Conditions
HIV InfectionsImmunological Abnormality
Interventions
DRUG

Rillus®

Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.

OTHER

Placebo

Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.

Trial Locations (1)

10430

HIV Clinic, Cipto Mangunkusumo Hospital, Jakarta

All Listed Sponsors
lead

Indonesia University

OTHER

NCT03568812 - The Role of Probiotics in HIV Patients With Immunological Non-Responder | Biotech Hunter | Biotech Hunter